• DKSH has agreed to acquire 100% of NewBridge Pharmaceuticals at an enterprise value of USD 390 million.
• The Dubai-based healthcare commercialization platform operates across 14 Middle Eastern and North African markets, expanding the buyer's healthcare footprint beyond Asia Pacific.
• NewBridge expects net sales of around USD 385 million in 2027, with a high-single-digit EBITDA margin.
• The debt-financed acquisition is expected to close by the end of the first quarter of 2027, subject to customary closing conditions.
• The deal is expected to boost net sales growth, core EBIT margin and earnings per share from closing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DKSH Holding AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2417576_en) on October 19, 2026, and is solely responsible for the information contained therein.